Loading
Life sciences · Journal article
Oral Diseases · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Locally advanced oral squamous cell carcinoma (OSCC) remains surgically anchored, but systemic treatment is evolving rapidly, particularly with perioperative immunotherapy. METHODS: We reviewed clinical evidence on neoadjuvant, adjuvant, maintenance, and altered-dose systemic strategies for resectable locally advanced OSCC and relevant head and neck squamous cell carcinoma. RESULTS: Conventional neoadjuvant chemotherapy has not improved survival in unselected resectable OSCC and should be reserved for selected indications including borderline resectability, mandibular preservation, and conversion to surgery. Neoadjuvant immunotherapy studies using PD-1 blockade, dual checkpoint inhibition, chemoimmunotherapy, targeted-immunotherapy combinations, and SBRT-immunotherapy have demonstrated feasible delivery and meaningful pathological responses. KEYNOTE-689 established improved event-free survival with perioperative pembrolizumab. Postoperatively, cisplatin-radiotherapy remains standard for positive margins and extranodal extension, while NIVOPOST-OP supports nivolumab intensification in high-risk disease. Maintenance therapy remains uncertain, with negative MACE results but a possible benefit from tegafur-uracil in selected patients. CONCLUSION: Perioperative immunotherapy is reshaping resectable OSCC treatment. Postoperative intensification, maintenance therapy, and lower-dose strategies, including low-dose nivolumab with metronomic therapy, require prospective validation. These approaches may be especially important in resource-constrained settings, where treatment cost and access remain major barriers.